IL-6 serum level, ARDS, and AKI as risk factors for the COVID-19 infection’s mortality in children
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0293639 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Idham Jaya Ganda und 8 weiteren Autor:innen. Beteiligte Einrichtung: Emergency and Pediatric Intensive Care Division, Department of Pediatrics, Faculty of Medicine Hasanuddin University, Makassar, Indonesia. Hauptthemen laut MEDLINE: Acute Kidney Injury, COVID-19, Respiratory Distress Syndrome. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Introduction
Dysregulated immune responses are developed in Coronavirus disease-2019 (COVID-19) and Interleukin-6 (IL-6) levels are reflecting the severity of the clinical presentation. This study aimed to analyze IL-6 serum level, Acute Respiratory Distress Syndrome (ARDS), and Acute Kidney Injury (AKI) as risk factors for mortality in children with COVID-19.
Methods
This prospective cohort study was conducted on children with COVID-19 infection confirmed by Real Time Polymerase Chain Reaction (RT-PCR) who were admitted to infection center at Dr. Wahidin Sudirohusodo Hospital from September 2021 to September 2022. Subjects were selected using the consecutive sampling method.
Results
A total of 2,060 COVID-19 RT-PCR tests were performed, and 1,065 children were confirmed positive. There were 291 cases that met the inclusion criteria, with 28.52 percent non-survives and 71.48% survives. The risk factors for mortality were IL-6, ARDS, AKI, Prothrombin Time / Activated Partial Thromboplastin Time (PT/aPTT), oxygen saturation, Absolut lymphocyte count (ALC), leukocytes, Length of Stay (LOS), and nutritional status (p80.97 pg/ml with 93% sensitivity and 90% specificity. Area Under Curve was 0.981 (95% CI), 0.960–1.000). A multivariate analysis showed IL-6 levels with OR 18.570 (95% CI 5.320–64.803), ARDS with Odds Ratio (OR) 10.177, (95% Confidence Interval (CI) 1.310–9.040), and AKI with OR 3.220 (95% CI 1.070–10.362). A combination of increased IL-6, ARDS, and AKI can predict a mortality probability as high as 98.3%.
Conclusion
IL-6, ARDS, and AKI are risk factors for mortality in children with COVID-19. IL-6 level was the highest mortality risk factor.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Emergency and Pediatric Intensive Care Division, Department of Pediatrics, Faculty of Medicine Hasanuddin University, Makassar, Indonesia.
- Child Health Department, DR Wahiddin Sudirohusodo Hospital, Makassar, Indonesia.
- Department of Pediatrics, Faculty of Medicine Hasanuddin University, Makassar, Indonesia.
- Nephrology Division, Department of Pediatrics, Faculty of Medicine Hasanuddin University, Makassar, Indonesia.
- Respirology Division, Department of Pediatrics, Faculty of Medicine Hasanuddin University, Makassar, Indonesia.
- Infection & Tropical Disease Division, Department of Pediatrics, Faculty of Medicine Hasanuddin University, Makassar, Indonesia.
ORCID-Profile: Idham Jaya Ganda
Zitieren
APA
Ganda, I. J., Putri, T. K. E., Rauf, S., Laompo, A., Pelupessy, N. M., Lawang, S. A., Ridha, N. R., Fikri, B., & Massi, M. N. (2023). IL-6 serum level, ARDS, and AKI as risk factors for the COVID-19 infection’s mortality in children. PLOS ONE. https://doi.org/10.1371/journal.pone.0293639
Vancouver
Ganda IJ, Putri TKE, Rauf S, Laompo A, Pelupessy NM, Lawang SA, et al. IL-6 serum level, ARDS, and AKI as risk factors for the COVID-19 infection’s mortality in children. PLOS ONE. 2023. doi:10.1371/journal.pone.0293639
BibTeX
@article{Ganda2023,
author = {Ganda, Idham Jaya and Putri, Try Kartika Eka and Rauf, Syarifuddin and Laompo, Amiruddin and Pelupessy, Ninny Meutia and Lawang, Sitti Aizah and Ridha, Nadirah Rasyid and Fikri, Bahrul and Massi, Muhammad Nasrum},
title = {IL-6 serum level, ARDS, and AKI as risk factors for the COVID-19 infection’s mortality in children},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0293639}
}
EUVIMED